{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:30:27Z","timestamp":1790775027604,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Genome-wide association studies have identified several genetic variants associated with nonalcoholic fatty liver disease. To emphasize metabolic abnormalities in fatty liver, metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been introduced; thus, we aimed to investigate single-nucleotide polymorphisms related to MAFLD and its subtypes. A genome-wide association study was performed to identify genetic factors related to MAFLD. We used a Korean population-based sample of 2282 subjects with MAFLD and a control group of 4669. We replicated the results in a validation sample which included 639 patients with MAFLD and 1578 controls. Additionally, we categorized participants into three groups, no MAFLD, metabolic dysfunction (MD)-MAFLD, and overweight\/obese-MAFLD. After adjusting for age, sex, and principal component scores, rs738409 [risk allele G] and rs3810622 [risk allele T], located in the <jats:italic>PNPLA3<\/jats:italic> gene, showed significant associations with MAFLD (<jats:italic>P<\/jats:italic>-values, discovery set\u2009=\u20091.60\u2009\u00d7\u200910<jats:sup>\u201315<\/jats:sup> and 4.84\u2009\u00d7\u200910<jats:sup>\u201310<\/jats:sup>; odds ratios, 1.365 and 1.284, validation set\u2009=\u20091.39\u2009\u00d7\u200910<jats:sup>\u20134<\/jats:sup>, and 7.15\u2009\u00d7\u200910<jats:sup>\u20134<\/jats:sup>, odds ratios, 1.299 and 1.264, respectively). An additional SNP rs59148799 [risk allele G] located in the <jats:italic>GATAD2A<\/jats:italic> gene showed a significant association with MAFLD (<jats:italic>P<\/jats:italic>-values, discovery set\u2009=\u20092.08\u2009\u00d7\u200910<jats:sup>\u20138<\/jats:sup> and validation set\u2009=\u20090.034, odds ratios, 1.387 and 1.250). rs738409 was significantly associated with MAFLD subtypes ([overweight\/obese-MAFLD; odds ratio (95% confidence interval),<jats:italic> P<\/jats:italic>-values, 1.515 (1.351\u20131.700), 1.43\u2009\u00d7\u200910<jats:sup>\u201312<\/jats:sup> and MD-MAFLD: 1.300 (1.191\u20131.416), 2.90\u2009\u00d7\u200910<jats:sup>\u20139<\/jats:sup>]. There was a significant relationship between rs3810622 and overweight\/obese-MAFLD and MD-MAFLD [odds ratios (95% confidence interval), <jats:italic>P<\/jats:italic>-values, 1.418 (1.258, 1.600), 1.21\u2009\u00d7\u200910<jats:sup>\u20138<\/jats:sup> and 1.225 (1.122, 1.340), 7.06\u2009\u00d7\u200910<jats:sup>\u20136<\/jats:sup>,\u00a0respectively]; the statistical significance remained in the validation set. <jats:italic>PNPLA3<\/jats:italic> was significantly associated with MAFLD and MAFLD subtypes in the Korean population. These results indicate that genetic factors play an important role in the pathogenesis of MAFLD.<\/jats:p>","DOI":"10.1038\/s41598-024-60152-0","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T01:01:25Z","timestamp":1714352485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population"],"prefix":"10.1038","volume":"14","author":[{"given":"Young","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ju","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyung","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Sun","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong In","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Won","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Yoon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goh Eun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"5","key":"60152_CR1","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik, J. M., Golabi, P., Younossi, Y., Mishra, A. & Younossi, Z. M. Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD. Hepatology 72(5), 1605\u20131616 (2020).","journal-title":"Hepatology"},{"issue":"3","key":"60152_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. Non-alcoholic fatty liver disease-a global public health perspective. J. Hepatol. 70(3), 531\u2013544 (2019).","journal-title":"J. Hepatol."},{"issue":"Suppl","key":"60152_CR3","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.3350\/cmh.2022.0318","volume":"29","author":"S Sookoian","year":"2023","unstructured":"Sookoian, S. & Pirola, C. J. Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response. Clin. Mol. Hepat. 29(Suppl), S184-s195 (2023).","journal-title":"Clin. Mol. Hepat."},{"issue":"2","key":"60152_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12328-018-0841-9","volume":"11","author":"Y Seko","year":"2018","unstructured":"Seko, Y., Yamaguchi, K. & Itoh, Y. The genetic backgrounds in nonalcoholic fatty liver disease. Cli.n J. Gastroenterol. 11(2), 97\u2013102 (2018).","journal-title":"Cli.n J. Gastroenterol."},{"issue":"3","key":"60152_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","volume":"73","author":"QM Anstee","year":"2020","unstructured":"Anstee, Q. M. et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(\u2606). J. Hepatol. 73(3), 505\u2013515 (2020).","journal-title":"J. Hepatol."},{"issue":"3","key":"60152_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.5009\/gnl17306","volume":"12","author":"GE Chung","year":"2018","unstructured":"Chung, G. E. et al. Genetic polymorphisms of PNPLA3 and SAMM50 are associated with nonalcoholic fatty liver disease in a Korean population. Gut Liver 12(3), 316\u2013323 (2018).","journal-title":"Gut Liver"},{"issue":"1","key":"60152_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73(1), 202\u2013209 (2020).","journal-title":"J. Hepatol."},{"issue":"2","key":"60152_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3350\/cmh.2021.0067","volume":"27","author":"SH Kang","year":"2021","unstructured":"Kang, S. H., Cho, Y., Jeong, S. W., Kim, S. U. & Lee, J. W. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?. Clin. Mol. Hepatol. 27(2), 257\u2013269 (2021).","journal-title":"Clin. Mol. Hepatol."},{"issue":"12","key":"60152_CR9","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","volume":"40","author":"S Yamamura","year":"2020","unstructured":"Yamamura, S. et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 40(12), 3018\u20133030 (2020).","journal-title":"Liver Int."},{"key":"60152_CR10","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","volume":"19","author":"VH Nguyen","year":"2021","unstructured":"Nguyen, V. H., Le, M. H., Cheung, R. C. & Nguyen, M. H. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin. Gastroenterol. Hepatol. 19, 2172 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"60152_CR11","doi-asserted-by":"publisher","first-page":"693507","DOI":"10.3389\/fmed.2021.693507","volume":"8","author":"Q Huang","year":"2021","unstructured":"Huang, Q., Zou, X., Wen, X., Zhou, X. & Ji, L. NAFLD or MAFLD: Which has closer association with all-cause and cause-specific mortality?-Results from NHANES III. Front. Med. (Lausanne) 8, 693507 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"60152_CR12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1007\/s12072-022-10407-7","volume":"16","author":"H Lee","year":"2022","unstructured":"Lee, H., Lim, T. S., Kim, S. U. & Kim, H. C. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population. Hepatol. Int. 16, 1308\u20131317 (2022).","journal-title":"Hepatol. Int."},{"issue":"1","key":"60152_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12916-022-02716-3","volume":"21","author":"GE Chung","year":"2023","unstructured":"Chung, G. E. et al. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease. BMC Med. 21(1), 4 (2023).","journal-title":"BMC Med."},{"key":"60152_CR14","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/hep.32499","volume":"76","author":"ZM Younossi","year":"2022","unstructured":"Younossi, Z. M. et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?. Hepatology 76, 1423\u20131437 (2022).","journal-title":"Hepatology"},{"issue":"Suppl","key":"60152_CR15","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","volume":"29","author":"C Gofton","year":"2023","unstructured":"Gofton, C., Upendran, Y., Zheng, M. H. & George, J. MAFLD: How is it different from NAFLD?. Clin. Mol. Hepatol. 29(Suppl), S17-s31 (2023).","journal-title":"Clin. Mol. Hepatol."},{"issue":"2","key":"60152_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/liv.15139","volume":"42","author":"I Ayada","year":"2022","unstructured":"Ayada, I. et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. Liver Int. 42(2), 277\u2013287 (2022).","journal-title":"Liver Int."},{"issue":"9","key":"60152_CR17","doi-asserted-by":"publisher","first-page":"e24626","DOI":"10.1002\/jcla.24626","volume":"36","author":"S Liao","year":"2022","unstructured":"Liao, S. et al. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China. J. Clin. Lab. Anal. 36(9), e24626 (2022).","journal-title":"J. Clin. Lab. Anal."},{"issue":"1","key":"60152_CR18","doi-asserted-by":"publisher","first-page":"e0227357","DOI":"10.1371\/journal.pone.0227357","volume":"15","author":"SW Oh","year":"2020","unstructured":"Oh, S. W. et al. Genome-wide association study of metabolic syndrome in Korean populations. PLoS One 15(1), e0227357 (2020).","journal-title":"PLoS One"},{"key":"60152_CR19","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1016\/j.cgh.2021.06.042","volume":"20","author":"W Sohn","year":"2021","unstructured":"Sohn, W., Kwon, H. J., Chang, Y., Ryu, S. & Cho, Y. K. Liver Fibrosis in Asians with metabolic dysfunction-associated fatty liver disease. Clin. Gastroenterol. Hepatol. 20, e1135 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"60152_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nmeth.2307","volume":"10","author":"O Delaneau","year":"2013","unstructured":"Delaneau, O., Zagury, J. F. & Marchini, J. Improved whole-chromosome phasing for disease and population genetic studies. Nat. Methods 10(1), 5\u20136 (2013).","journal-title":"Nat. Methods"},{"issue":"6","key":"60152_CR21","doi-asserted-by":"publisher","first-page":"e1000529","DOI":"10.1371\/journal.pgen.1000529","volume":"5","author":"BN Howie","year":"2009","unstructured":"Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 5(6), e1000529 (2009).","journal-title":"PLoS Genet"},{"issue":"3","key":"60152_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1006\/tpbi.2001.1542","volume":"60","author":"B Devlin","year":"2001","unstructured":"Devlin, B., Roeder, K. & Wasserman, L. Genomic control, a new approach to genetic-based association studies. Theor. Popul. Biol. 60(3), 155\u2013166 (2001).","journal-title":"Theor. Popul. Biol."},{"issue":"18","key":"60152_CR23","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/bioinformatics\/btq419","volume":"26","author":"RJ Pruim","year":"2010","unstructured":"Pruim, R. J. et al. LocusZoom: Regional visualization of genome-wide association scan results. Bioinformatics 26(18), 2336\u20132337 (2010).","journal-title":"Bioinformatics"},{"key":"60152_CR24","doi-asserted-by":"publisher","first-page":"204201882211321","DOI":"10.1177\/20420188221132138","volume":"13","author":"X Zhu","year":"2022","unstructured":"Zhu, X., Xia, M. & Gao, X. Update on genetics and epigenetics in metabolic associated fatty liver disease. Ther. Adv. Endocrinol. Metab. 13, 20420188221132136 (2022).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"10","key":"60152_CR25","doi-asserted-by":"publisher","first-page":"e13331","DOI":"10.1111\/eci.13331","volume":"50","author":"A Ismaiel","year":"2020","unstructured":"Ismaiel, A. & Dumitrascu, D. L. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-systematic review. Eur. J. Clin. Invest. 50(10), e13331 (2020).","journal-title":"Eur. J. Clin. Invest."},{"issue":"12","key":"60152_CR26","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40(12), 1461\u20131465 (2008).","journal-title":"Nat. Genet."},{"issue":"4","key":"60152_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ajhg.2008.09.012","volume":"83","author":"X Yuan","year":"2008","unstructured":"Yuan, X. et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am. J. Hum. Genetics 83(4), 520\u2013528 (2008).","journal-title":"Am. J. Hum. Genetics"},{"issue":"3","key":"60152_CR28","doi-asserted-by":"publisher","first-page":"e1001324","DOI":"10.1371\/journal.pgen.1001324","volume":"7","author":"EK Speliotes","year":"2011","unstructured":"Speliotes, E. K. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7(3), e1001324 (2011).","journal-title":"PLoS Genet."},{"issue":"6","key":"60152_CR29","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/hep.24283","volume":"53","author":"S Sookoian","year":"2011","unstructured":"Sookoian, S. & Pirola, C. J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53(6), 1883\u20131894 (2011).","journal-title":"Hepatology"},{"issue":"6","key":"60152_CR30","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1002\/hep.30583","volume":"69","author":"Y Wang","year":"2019","unstructured":"Wang, Y., Kory, N., BasuRay, S., Cohen, J. C. & Hobbs, H. H. PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice. Hepatology 69(6), 2427\u20132441 (2019).","journal-title":"Hepatology"},{"issue":"12","key":"60152_CR31","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/apt.15738","volume":"51","author":"B Carlsson","year":"2020","unstructured":"Carlsson, B. et al. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 51(12), 1305\u20131320 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"33","key":"60152_CR32","doi-asserted-by":"publisher","first-page":"e4569","DOI":"10.1097\/MD.0000000000004569","volume":"95","author":"G Song","year":"2016","unstructured":"Song, G. et al. Association of patatin-like phospholipase domain-containing protein 3 gene polymorphisms with susceptibility of nonalcoholic fatty liver disease in a Han Chinese population. Med. (Baltimore) 95(33), e4569 (2016).","journal-title":"Med. (Baltimore)"},{"issue":"1","key":"60152_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.yexmp.2018.01.001","volume":"104","author":"E Larrieta-Carrasco","year":"2018","unstructured":"Larrieta-Carrasco, E. et al. Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. Exp. Mol. Pathol. 104(1), 50\u201358 (2018).","journal-title":"Exp. Mol. Pathol."},{"issue":"7","key":"60152_CR34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00439-013-1294-3","volume":"132","author":"T Kitamoto","year":"2013","unstructured":"Kitamoto, T. et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum. Genet. 132(7), 783\u2013792 (2013).","journal-title":"Hum. Genet."},{"issue":"1","key":"60152_CR35","doi-asserted-by":"publisher","first-page":"e0185490","DOI":"10.1371\/journal.pone.0185490","volume":"13","author":"T Kawaguchi","year":"2018","unstructured":"Kawaguchi, T. et al. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS One 13(1), e0185490 (2018).","journal-title":"PLoS One"},{"issue":"10","key":"60152_CR36","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/hep4.1751","volume":"5","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. Association of genetic risk score with NAFLD in an ethnically diverse cohort. Hepatol. Commun. 5(10), 1689\u20131703 (2021).","journal-title":"Hepatol. Commun."},{"key":"60152_CR37","doi-asserted-by":"publisher","first-page":"9282557","DOI":"10.1155\/2022\/9282557","volume":"2022","author":"T Mu","year":"2022","unstructured":"Mu, T. et al. Single nucleotide polymorphism of genes associated with metabolic fatty liver disease. J. Oncol. 2022, 9282557 (2022).","journal-title":"J. Oncol."},{"issue":"3","key":"60152_CR38","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5009\/gnl210167","volume":"16","author":"JH Moon","year":"2022","unstructured":"Moon, J. H., Kim, W., Koo, B. K. & Cho, N. H. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease. Gut Liver 16(3), 433\u2013442 (2022).","journal-title":"Gut Liver"},{"key":"60152_CR39","doi-asserted-by":"crossref","unstructured":"Korean Association for the Study of the L: KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 19(4), 325\u2013348 (2013).","DOI":"10.3350\/cmh.2013.19.4.325"},{"key":"60152_CR40","doi-asserted-by":"crossref","unstructured":"Chalasani, N., Younossi, Z., Lavine, JE., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, M., Sanyal, A.J., American Gastroenterological A, American Association for the Study of Liver D et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 142(7), 1592\u20131609 (2012).","DOI":"10.1053\/j.gastro.2012.04.001"},{"issue":"3","key":"60152_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2009.05.023","volume":"51","author":"NF Schwenzer","year":"2009","unstructured":"Schwenzer, N. F. et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 51(3), 433\u2013445 (2009).","journal-title":"J. Hepatol."},{"key":"60152_CR42","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1038\/s41598-024-61718-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60152-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T12:13:59Z","timestamp":1715688839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-60152-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["60152"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-60152-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-024-61718-8","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-024-61718-8","URL":"https:\/\/doi.org\/10.1038\/s41598-024-61718-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9753"}}